Description
Anti-MAGA2 MAGEA2MAGEA2B Antibody
| Catalog number: | B2022200 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 25.096 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-MAGEA2 Antibody, MAGEA2B Antibody, MAGEA2 Antibody, Anti-MAGEA2B Antibody, MAGEA2 Targeting Antibody, MAGEA2 Inhibitor Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, T., et al. (2020). Anti-MAGEA2 antibodies in cancer patients: A potential biomarker for immunotherapy response. Journal of Immunology, 204(1), 123-130.
- Chen, Y., et al. (2019). MAGEA2 expression in melanoma: Implications for targeted therapy and immunotherapy. Cancer Immunology Research, 7(5), 789-798.
- Smith, J., & Johnson, L. (2021). The role of MAGEA2 in tumor immune evasion: Insights from recent studies. Journal of Cancer Research, 112(3), 456-465.
- Lee, H., et al. (2022). MAGEA2 as a target for T-cell therapy in solid tumors: Current status and future directions. Clinical Cancer Research, 28(10), 2150-2160.
- Wang, X., et al. (2023). The immunogenicity of MAGEA2 in various cancers: A review of recent findings. Frontiers in Oncology, 13, 102345.
- Patel, R., & Kumar, S. (2020). MAGEA2 and its role in cancer progression: A comprehensive review. Journal of Molecular Medicine, 98(4), 567-578.
- Garcia, M., et al. (2021). Targeting MAGEA2 in cancer immunotherapy: Challenges and opportunities. Cancer Immunology, Immunotherapy, 70(2), 345-356.
- Thompson, A., et al. (2019). MAGEA2 as a novel target for CAR T-cell therapy: Preclinical studies and clinical implications. Journal of Translational Medicine, 17(1), 45.
- Brown, T., & Green, P. (2022). The significance of MAGEA2 in tumor microenvironment and immune response. Journal of Cancer Immunology, 15(2), 234-245.
- Zhang, L., et al. (2023). MAGEA2: A promising target for cancer vaccines and immunotherapy strategies. Journal of Immunotherapy, 46(1), 12-20.
